Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • ChrysCapital makes...

    ChrysCapital makes Surprise bid for Mankind Pharma stake

    Written by Ruby Khatun Khatun Published On 19 March 2018 3:57 AM  |  Updated On 19 March 2018 3:57 AM
    ChrysCapital makes Surprise bid for Mankind Pharma stake

    Mumbai: As the Mankind, Pharma deal is entering in the last stage, it is expected to heat up and create a high competition between the firms. The investor firm ChrysCapital has made a surprise bid in the final stage in order to buy a stake in Mankind pharma as per a recent media report.


    Bankers directly aware of the matter told TOI that ChrysCapital along with its global sponsors has made a surprise late-stage bid to buy a stake of $350-400 million in Mankind Pharma.


    The step of the firm comes even as private equity giants Advent International and Carlyle Group already had made binding offers to buy up the 15 percent stake in Mankind Pharma.


    Read also: TOP Private Equity firms in race to buy stake in Mankind Pharma


    TOI reports that ChrysCapital is in the midst of a due diligence to buy around 10% stake.


    ChrysCapital will return to the Ramesh Juneja-led Mankind Pharma, if the deal goes through, as ChrysCapital had sold its 11 percent stake to Capital International last year. The promoters family controls 89 percent stake.

    The Juneja family is keen on getting ChrysCapital, arguably the most successful investor in Indian pharma, back on board. The fund’s partner and pharma industry veteran Sanjiv Kaul has strong ties with Indian pharma entrepreneurs, including the Junejas reports TOI.


    The Delhi based company Mankind Pharmaceuticals was founded in 1995 by Ramesh Juneja and Rajeev Juneja, having an intense focus on semi-urban and rural markets. Mankind Pharma focuses on a variety of therapeutic segments such as antibiotics, anti-fungal, gastro-intestinal, anthelmintic, cardiovascular, NSAIDs, dermal & erectile dysfunction. Some of its other brands include Addiction (deodorants for men), Gas-O-Fast (sachet for hyperacidity), Kaloree-1 (artificial sweetener) and Heal-O-Kind (anti-bacterial balm).


    The company has the presence in about 22 countries across Southeast Asia, Africa, and the Middle East, with the leading brand such as Manforce condoms, PregaNews and Unwanted 72. The company is best known for its over-the-counter (OTC) product portfolio and condoms sold under the brand Manforce.

    Advent InternationalCapital InternationalCarlyle GroupChrysCapitalManforce condomsMankindMankind PharmaMankind Pharma dealminority stakePregaNewsRamesh Junejasurprise bidUnwanted 72
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok